Tipiracil
- Generic Name
- Tipiracil
- Brand Names
- Lonsurf
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11ClN4O2
- CAS Number
- 183204-74-2
- Unique Ingredient Identifier
- NGO10K751P
- Background
Tipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its catabolism. TAS-102 is indicated for the treatment of metastatic colorectal cancer which has been previously treated with f...
- Indication
Tipiracil is also available as a combination product with Trifluridine, which is indicated either alone or in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wi...
- Associated Conditions
- Metastatic Colorectal Cancer (CRC), Metastatic Gastroesophageal Junction Adenocarcinoma
- Associated Therapies
- -
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
- Conditions
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 13
- Registration Number
- NCT04854434
- Locations
- 🇺🇸
Christiana Care Health Services, Christiana Hospital, Newark, Delaware, United States
🇺🇸BRCR Global, Plantation, Florida, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.